Aims To characterize milk/plasma (M/P) ratio and infant dose, for citalopram and demethylcitalopram, in breast-feeding women taking citalopram for the treatment of depression, and to determine the plasma concentration and effects of these drugs in their infants. Methods Seven women (mean age 30.6 years) taking citalopram (median dose 0.36 mg kg x1 day x1 ) and their infants (mean age 4.1 months) were studied. Citalopram and demethylcitalopram in plasma and milk were measured by highperformance liquid chromatography over a 24 h dose interval. Infant exposure was estimated (two separate methods) as the product of milk production rate and drug concentration in milk, normalized to body weight and expressed as a percentage of the weight-adjusted maternal dose. ) was detected in three of the seven infants. Demethylcitalopram (2.2 and 2.2 mg l x1 ) was detected in plasma from two of the same infants. No adverse effects were seen in the infants, all were within appropriate percentile limits for weight and all had normal Denver developmental quotients. Conclusions The mean combined dose of citalopram and demethylcitalopram (4.4±5.1% as citalopram equivalents) transmitted to infants via breast milk is below the 10% notional level of concern. Plasma concentrations of these drugs in the infants were very low or absent and there were no adverse effects. These data support the safety of the use of citalopram in breast feeding women. Nevertheless, each decision to breast feed should always be made as an individual risk:bene®t analysis.
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Introduction
Citalopram, a bicyclic isobenzofuran derivative [1] is a selective serotonin reuptake inhibitor. It is a racemic mixture of the (±)-R-and (+)-S-enantiomers, with the latter having the most potent and selective effect on 5-hydroxytryptamine uptake. Bioavailability after oral administration is approximately 80%, with peak plasma levels occurring 2±4 h after a dose [2, 3] . The volume of distribution is 12±16 l kg x1 [2] and the elimination halflife of citalopram is approximately 37 h [3] . Citalopram is lipid soluble and is metabolized in the liver mainly to a primary metabolite N-demethylcitalopram, which is then converted to N-didemethylcitalopram [4] . Three different cytochrome P450 isoforms are thought to be involved in its disposition (CYP2C19, CYP3A4 and CYP2D6 [5] );. The demethylated metabolites are less potent in vitro as serotonin reuptake inhibitors and are less able to penetrate to the brain [6] . The plasma protein binding of citalopram and its metabolites is approximately 50±80% [2] . Citalopram is also a weak inhibitor of cytochrome P4502D6 and has a minimal propensity to cause drug interactions with other CYP2D6 drug substrates [2] .
A major depressive disorder will occur in around 13% of women in the postnatal period, and a substantive number of these women will bene®t from the use of antidepressant medication [7] . In recent years the drive to breast feed babies has undergone a resurgence for biological, psychological and social reasons. Lactating women who are recommended to commence an antidepressant have understandable concerns about the possible transfer of psychotropic medication into the breast milk and thence to their neonate. To assist in this area of patient management, we have studied the transfer of citalopram and demethylcitalopram into milk in seven lactating women and related this data to plasma concentrations and effects in their breast-fed infants.
Methods

Patients
Seven breast-feeding women (mean age 31 years, range 24±36 years; mean body weight 62.6 kg, range 52±70 kg) and their infants (3 M and 4 F; mean age=4.1 months, range 1.9±6.6 months) were enrolled in the study. The median dose of citalopram ingested by the women was 0.36 (range 0.29±0.58) mg kg x1 day
x1
. Therapy with citalopram had commenced a mean of 97 (range 49±183) days prior to the study day, and all participants were considered to be at steady-state at the time of study.
Study protocol
The study was approved by the Ethics Committee of King Edward Memorial and Princess Margaret Hospitals, and written informed consent was obtained from all participants.
Data collection
The mothers were admitted to the research ward at 07.30 h, and had a venous catheter inserted into a forearm vein immediately prior to the morning dose of citalopram at 08.00 h. Venous blood samples (8 ml, heparinized) were collected via the catheter at 0, 2, 4, 6 and 8 h postdose, and also by venepuncture at 12 and 24 h. At the same time intervals, both breasts were emptied via an electric or manual breast pump. Milk volumes were recorded and 15 ml aliquots were retained for drug assay. A sample of milk was also collected directly into a 1 ml blood-gas syringe (Bard-Parker, Becton-Dickinson, NJ, USA) and pH was measured using a NOVA StatPro®le 1 blood gas analyser (NOVA Biomedical, Waltham MA, USA). Preliminary experiments established that the pH and pCO 2 of samples collected using this procedure did not change signi®cantly over a 9 h period (data not shown). Creamatocrit (% fat in milk) for each milk sample was measured as previously described [8] . The remainder of the milk was bottle-fed to the infants as required. The women were discharged from hospital after 8 h and milk and plasma samples at 12 and 24 h postdose were collected at the patient's home. All women gave consent for a venous blood sample (0.5±1 ml, heparinized) to be taken from their infants. Infant blood samples were collected at a mean of 6.5 (6.2, 6.8) h after the maternal dose.
For all studies, infant health and well being were evaluated by enquiry of the mother together with a full clinical examination by a specialist neonatologist (RK). Infant body weight for age was checked against genderspeci®c population percentile graphs and a Denver developmental screening test was performed [9, 10] . Results for the latter were expressed as the quotient of age as assessed by the Denver test as a percent of chronological age.
Materials
Citalopram and demethylcitalopram standards were donated by Lundbeck Australia Pty Ltd, and desipramine hydrochloride by Novartis Pharmaceuticals Australia Pty Ltd. All solvents and other chemicals were of analytical or h.p.l.c. grade.
High performance liquid chromatography (h.p.l.c.)
Following the addition of desipramine (100 ng) as an internal standard, 1 ml aliquots of plasma were made alkaline with 0.1 ml of 1 M NaOH and the analytes were extracted into 10 ml 1% isoamylalcohol in hexane by shaking vigorously for 5 min. After centrifugation (1500 g for 5 min), the organic phase (9 ml) was back-extracted into 0.2 ml 0.05 M HCl by vortexing for 1 min, and 0.05±0.1 ml aliquots of the acid phase were injected into the h.p.l.c. Milk samples were extracted in a similar manner except that the`method of addition' was used. Rac-citalopram and rac-demethylcitalopram concentrations in milk were determined by taking four equal aliquots of each milk sample (1 ml) and spiking three of these with increasing concentrations of authentic citalopram and demethylcitalopram. The samples were then extracted and analysed as for plasma. The h.p.l.c. system consisted of a Merck RP Select B C 18 column (250r4.6 mm), a mobile phase of 40% acetonitrile containing 0.01% sodium chloride and 0.01% H 3 PO 4 (1.6 ml min x1 ), with u.v. detection at 210 nm. Plasma drug concentrations were interpolated from a standard curve (peak height ratio analyte: desipramine vs analyte concentration (r 2 >0.995). For milk, a standard curve (peak height ratio analyte: desipramine vs added analyte concentration (r 2 >0.995) was constructed and drug concentrations were determined from the negative x-axis intercept. Coef®cients of variation (CV) were measured at 25 and 250 mg l x1 for both citalopram and demethylcitalopram. Intra-day CV (both analytes) ranged from 1.7 to 5.5% for plasma and 4.7±6.4% for milk, while interday CV ranged from 2.9 to 8.2% for plasma and from 5.8 to 13.2% for milk. The limit of detection for both analytes in milk and plasma was 1 mg l x1 .
Measurement of plasma protein binding
Protein binding for citalopram and demethylcitalopram (one sample from each of ®ve volunteers) was measured by ultra®ltration using Amicon Centrifree YM-30 centrifugal ®lter devices (Millipore Corporation, MA, USA) and the h.p.l.c. method described above.
Measurement of octanol:buffer partition coef®cients
Citalopram and demethylcitalopram (each 10 mg l x1 ) were dissolved in 0.02 M phosphate buffer (pH 7.2) and aliquots were equilibrated with an equal volume of n-octanol by shaking vigorously for 10 min. The concentration of each analyte in the buffer was determined before and after the extraction process using the above h.p.l.c. method and log 10 P values calculated from these data.
Statistical evaluation of data
Data have been summarized as mean (95% CI, or range), or median (range) as appropriate. Difference between mean infant dose calculated by two different methods was assessed using a paired Student's t-test. Differences between milk pH or creamatocrit between patients and collection times were assessed by 2-way ANOVA. Repeated measures 2-way ANOVA was used to investigate the relationship between M/P and milk pH, creamatocrit and subjects for both citalopram and demethylcitalopram. 2-way ANOVA was also used to investigate inter and intravolunteer variability in milk pH and creamatocrit.
Calculation of milk/plasma ratios and infant dose
Area under the concentration-time pro®les (AUC(0, 24 h)) was calculated using the log trapezoidal rule [11] for plasma, and rectangular areas for milk (S concentrationrcollection time). Milk/plasma ratios (M/P AUC ) were calculated from these AUC data, and also from milk and plasma concentrations measured at each collection time (M/P). The absolute infant citalopram or demethylcitalopram (as citalopram equivalents) dose was calculated by two separate methods, both assuming an oral bioavailability of 100%. In method A, the measured cumulative drug excretion over 24 h (S milk concentration for each collection periodrvolume) was divided by the infant's body weight to give a dose in mg kg x1 . In method B, an average infant intake of 0.15 l milk kg x1 day x1 was assumed [12] , and this value was multiplied by the average milk concentration (AUC milk /dose interval time) to give a dose in mg kg x1 . For both methods, the infant dose was then expressed as a percentage of the maternal weight-normalized dose. M/P for citalopram was also calculated directly from a knowledge of its pKa (9.5; data on ®le, Lundbeck Australia Pty Ltd), plasma protein binding and log 10 P (octanol:buffer, pH 7.2) according to the method of Begg et al. [13] .
Results
Mean plasma and milk concentration-time pro®les for citalopram and demethylcitalopram (n=7) are shown in Figure 1 . Peak drug concentrations occurred at a mean of 3.9 h and 5.7 h after dose for citalopram and demethylcitalopram, respectively ( (Table 1) . M/P-values calculated at each collection time were subjected to repeated measures 2-way ANOVA using milk pH, creamatocrit and volunteers as independent factors, but no signi®cant relationships were present (P>0.05) for either citalopram or demethylcitalopram. lents. Infant dose was calculated by two different methods. The mean (95% CI) absolute infant doses calculated by method A (actual cumulative drug excretion) were 3.2% (1.9, 4.6) and 1.2% (0.7, 1.7) for citalopram and demethylcitalopram, respectively. Doses calculated by method B (assuming an estimated infant milk intake of 0.15 l kg x1 day x1 ) were 3.7% (2.6, 4.8) for citalopram and 1.4% (0.9, 1.9) for demethylcitalopram. There were no signi®cant differences between the mean infant doses calculated by either method. The mean milk pH for the whole group was 7.23 (7.09, 7.37). Two-way ANOVA showed that milk pH varied signi®cantly between volunteers (F=14.8, P<0.001) but not between collection times. Mean creamatocrit for the whole group was 4.8% (4.1, 5.5). There were signi®cant differences in creamatocrit between volunteers (F=2.8, P=0.024) and between collection times (F=4.6, P=0.002).
Low concentrations (around 2±2.3 mg l x1 ) of citalopram and demethylcitalopram were detected in plasma from three and two of the seven infants, respectively ( Table 2 ). None of the mothers reported any adverse effects in their infants and a full clinical examination revealed no motor or tone abnormalities. Infant weights at the time of study (mean = 6.2 kg, range 3.7±9.1 kg) were within the same (or greater) percentiles as they were at birth (mean = 3.2, range 2.5±3.8 kg). Values for the Denver development quotient were normal for age (median = 100%, range 100±119%).
Log P octanol:buffer pH 7.2-values for citalopram and demethylcitalopram were 1.452 and 0.242, respectively. Mean plasma protein binding (®ve patients) was 70.9% (65.2±76.6) for citalopram and 67.5% (60.7±74.3) for demethylcitalopram. Calculation of the theoretical M/P for citalopram [14] , using the above log P value, a mean milk pH of 7.2 and assuming 71% protein binding gave a value of 1.3. Varying the percent protein binding in this calculation (from 65 to 77%=the 95% CI) gave a predicted M/P varying from 1.5 to 1.1, respectively.
Discussion
Although both citalopram and its major metabolites have enantiomers with modest differences in their pharmacokinetics [15, 16] , in the present study we were primarily interested in maximum infant exposure and have therefore con®ned our attention to the racemates of citalopram and its major metabolite demethycitalopram. Milk pH averaged 7.23 with signi®cant intervolunteer variation, but no signi®cant variation across the various sampling times. Creamatocrit showed signi®cant variation both between volunteers and across collection times. However, neither milk pH nor creamatocrit were signi®cant predictors of M/P after intervolunteer variability was isolated. We were not able to include plasma protein binding in this analysis as we had made only one measurement from ®ve of the seven volunteers. The citalopram concentration-time pro®le in milk showed a similar mean peak:trough concentration ratio (1.6) to that for its demethyl metabolite (1.4). M/P AUC also was similar (1.8) for both citalopram and demethylcitalopram. The similar extent of transfer of these analytes into milk occurred despite the higher log P value for citalopram. Overall, our data suggest that lipid solubility, milk pH and creamatocrit are not the major determinant variables for transfer of these drugs into milk. In this regard, it has previously been noted that plasma protein binding can often be highly in¯uential in drug transfer to milk [13] . Theoretical prediction of the M/P for citalopram by the method of Begg et al. [13] gave a value of 1.3, which was at the lower end of the 95% CI for the mean measured value (1.0±2.5). This con®rmed that this method is useful in the absence of actual patient data. M/P changed inversely with percent binding of citalopram in plasma. Increasing percent bound from 71 to 77% decreased predicted M/ P from 1.3 to 1.1 (15%).
There are two published papers describing the excretion of citalopram into breast milk. Jensen [17] studied a single mother and baby pair and quoted an M/P < 3 for both citalopram and N-demethylcitalopram. Peak milk concentrations occurred 3±9 h after dose. Both citalopram and N-demethylcitalopram were detected in trace amounts in infant's plasma after 3 weeks exposure to citalopram via breast milk. The plasma concentration of citalopram in the infant was 2.3 mg l x1 (7 nM) and the dose received by the infant was < 5% of weight adjusted maternal dose. In the second study by Spigset et al. [18] , data from two breast feeding mothers with depression, and one healthy volunteer were reported. In the depressed patients, M/P for citalopram ranged from 1.66 to 1.88 based on single paired measurements in plasma and milk. Data for N-demethylcitalopram were not provided. The relative infant dose of citalopram was calculated to be 0.7±5.9% of the maternal dose. No adverse effects were observed in the infants. Based on AUC data for citalopram in the healthy volunteer subject, M/P and relative infant dose were estimated to be 1 and 1.8% (of the maternal dose), respectively. Values for M/P and estimated infant dose from the above studies were similar to the de®nitive data from our present investigation. We found an M/ P AUC of 1.8 for both citalopram and demethylcitalopram with a similar degree of interpatient (Table 1 ) and intrapatient (data not shown) variability. Thus, in our view, AUC measurements remain the preferred data source for calculating M/P.
Two different methods for calculating infant dose were tested. Both gave similar values for infant dose, con®rming that milk production in this cohort of mothers (0.13 l kg x1 day
x1
) was similar to the population average (0.15 l kg x1 day x1 ) [12] . This is different from the situation with sertraline [19] where an apparently lower milk production resulted in lower estimates of infant dose with method A.
In summary, no adverse effects were reported by the mothers, or noted on clinical examination, in any of the breast-fed infants in the study. All had body weights that were within appropriate percentile limits for age and they showed normal development for age as assessed by the Denver developmental screening test. Moreover, drug transfer was lower (mean of around 5%) than the notional 10% level of concern [12] , and only very low plasma concentrations of drug were found in less than half of the infants. Taken together, these data suggest that citalopram is likely to be safe for use during breast feeding. Nevertheless, each decision to breast feed should always be made as an individual risk:bene®t analysis.
